1. Home
  2. NCRA vs ENLV Comparison

NCRA vs ENLV Comparison

Compare NCRA & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.45

Market Cap

3.5M

ML Signal

HOLD

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$2.56

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
ENLV
Founded
2002
2005
Country
Taiwan
Israel
Employees
N/A
34
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
4.0M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
NCRA
ENLV
Price
$1.45
$2.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.4K
★ 1.7M
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $13,627,944.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.30
$0.16
52 Week High
$80.40
$7.64

Technical Indicators

Market Signals
Indicator
NCRA
ENLV
Relative Strength Index (RSI) 43.41 83.72
Support Level $1.30 $0.65
Resistance Level $1.83 $7.64
Average True Range (ATR) 0.11 0.10
MACD 0.00 0.32
Stochastic Oscillator 21.43 87.55

Price Performance

Historical Comparison
NCRA
ENLV

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Share on Social Networks: